NCT00222807View on ClinicalTrials.gov

Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
SchizophreniaSchizoaffective DisorderDelusional Disorder
Trial Locations (1)

15213

University of Pittsburgh, Pittsburgh

Sponsors

Collaborators (1)

Janssen Pharmaceuticals
All Listed Sponsors
collaborator

American Association for Geriatric Psychiatry

OTHER

collaborator

Janssen Pharmaceuticals

INDUSTRY

lead

University of Pittsburgh

OTHER

NCT00222807 - Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus | Biotech Hunter | Biotech Hunter